Pages that link to "Q28585898"
Jump to navigation
Jump to search
The following pages link to Apoptotic Cell Death in Mouse Models of GM2 Gangliosidosis and Observations on Human Tay-Sachs and Sandhoff Diseases (Q28585898):
Displaying 50 items.
- Hexosaminidase A (Q21984075) (← links)
- Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model. (Q27303930) (← links)
- Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of Sandhoff disease (Q27316065) (← links)
- Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates (Q27318381) (← links)
- Mice Doubly-Deficient in Lysosomal Hexosaminidase A and Neuraminidase 4 Show Epileptic Crises and Rapid Neuronal Loss (Q27346357) (← links)
- Biochemical consequences of mutations causing the GM2 gangliosidoses (Q28138411) (← links)
- Natural history of infantile G(M2) gangliosidosis (Q28251348) (← links)
- Glycosphingolipidoses: beyond the enzymatic defect (Q28290521) (← links)
- Pathology of GM2 Gangliosidosis in Jacob Sheep (Q28299661) (← links)
- Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease (Q28478879) (← links)
- Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice (Q28507753) (← links)
- A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder (Q28511052) (← links)
- Tay-Sachs disease mutations in HEXA target the α chain of hexosaminidase A to endoplasmic reticulum-associated degradation (Q28817048) (← links)
- FcRγ-dependent immune activation initiates astrogliosis during the asymptomatic phase of Sandhoff disease model mice (Q29248442) (← links)
- In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders (Q31028468) (← links)
- Thymic Alterations in GM2 Gangliosidoses Model Mice (Q33697973) (← links)
- Prostaglandin E2 Reverses Aberrant Production of an Inflammatory Chemokine by Microglia from Sandhoff Disease Model Mice through the cAMP-PKA Pathway (Q33813101) (← links)
- Multi-system disorders of glycosphingolipid and ganglioside metabolism (Q33902037) (← links)
- Mesenchymal stem cells as cellular vectors for pediatric neurological disorders (Q33918923) (← links)
- The Caenorhabditis elegans mucolipin-like gene cup-5 is essential for viability and regulates lysosomes in multiple cell types (Q34047933) (← links)
- Future perspectives for Tay-Sachs disease (Q34094763) (← links)
- Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease (Q34113690) (← links)
- From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system (Q34224260) (← links)
- On the role of natural killer cells in neurodegenerative diseases (Q34329075) (← links)
- Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology (Q34364491) (← links)
- Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis (Q34941895) (← links)
- Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses (Q35043211) (← links)
- Application of direct HPTLC-MALDI for the qualitative and quantitative profiling of neutral and acidic glycosphingolipids: the case of NEU3 overexpressing C2C12 murine myoblasts. (Q35077360) (← links)
- Methionine sulfoxide reductase A (MsrA) protects cultured mouse embryonic stem cells from H2O2-mediated oxidative stress (Q35077849) (← links)
- Elevation of GM2 ganglioside during ethanol-induced apoptotic neurodegeneration in the developing mouse brain (Q35886150) (← links)
- Peripheral nervous system manifestations in a Sandhoff disease mouse model: nerve conduction, myelin structure, lipid analysis. (Q35991172) (← links)
- Development of mammalian artificial chromosomes for the treatment of genetic diseases: Sandhoff and Krabbe diseases (Q36065953) (← links)
- Storage solutions: treating lysosomal disorders of the brain (Q36210235) (← links)
- Conditional expression of human β-hexosaminidase in the neurons of Sandhoff disease rescues mice from neurodegeneration but not neuroinflammation (Q36281480) (← links)
- TSPO in a murine model of Sandhoff disease: presymptomatic marker of neurodegeneration and disease pathophysiology (Q36396082) (← links)
- AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system (Q36482816) (← links)
- Patterns of cell signaling pathway activation that characterize mammary development. (Q36737572) (← links)
- Lysosomal Disorders Drive Susceptibility to Tuberculosis by Compromising Macrophage Migration. (Q36761911) (← links)
- Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis (Q36862161) (← links)
- Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. (Q37209173) (← links)
- Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation (Q37267731) (← links)
- Sequential proteolysis and high-field FTICR MS to determine disulfide connectivity and 4-maleimide TEMPO spin-label location in L126C GM2 activator protein (Q37377522) (← links)
- Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice (Q37381416) (← links)
- Reversibility of neuropathology in Tay-Sachs-related diseases (Q37463989) (← links)
- Lysosomal storage disease: revealing lysosomal function and physiology. (Q37739706) (← links)
- Neuronopathic lysosomal storage diseases: clinical and pathologic findings. (Q38116812) (← links)
- Metabolic correction in microglia derived from Sandhoff disease model mice (Q38322339) (← links)
- Differential gene expression in gamma-irradiated BALB/3T3 fibroblasts under the influence of 3-aminobenzamide, an inhibitior of parp enzyme. (Q38361987) (← links)
- AAV-mediated gene delivery attenuates neuroinflammation in feline Sandhoff disease (Q39236729) (← links)
- Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease. (Q39895074) (← links)